Shanghai Jeyou Pharmaceutical Technology Co., Ltd. (hereinafter referred to as “Jeyou Pharmaceutical”) has entered into an exclusive licensing agreement with Huya Bio International (hereinafter referred to as “Huya”). Under the agreement, Jeyou Pharmaceutical has granted Huya an exclusive license for the development, manufacturing, and commercialization of JMKX1899, a KRAS inhibitor with proprietary intellectual property rights, outside the Greater China region. Jeyou Pharmaceutical retains all rights to JMKX1899 within the Greater China region.

JMKX1899 is a KRAS inhibitor independently developed by Jeyou Pharma’s Small Molecule Innovation Center. Preclinical data indicate that, compared to products targeting the same pathway, JMKX1899 exhibits superior brain penetration and carries no risk of cardiotoxicity or drug-drug interactions. Jeyou Pharma submitted a clinical trial application to the National Medical Products Administration (NMPA) in October 2021. Jeyou Pharma and Huya will soon submit a clinical trial application to the U.S. Food and Drug Administration (FDA) to advance the clinical development of JMKX1899 in China and the United States simultaneously.

A senior executive at Jeyou Pharma stated: “We are delighted to partner with Huya Biopharma to develop this innovative KRAS inhibitor globally, bringing benefits to patients worldwide. This marks Jeyou Pharma’s first collaboration with an international partner since its founding in 2018, aimed at accelerating the global development of innovative Chinese drugs. HuYa International has accumulated extensive experience in collaborating with its Chinese partners; we are very much looking forward to the upcoming global clinical studies and hope that JMKX1899 will provide new treatment options for patients with KRAS-mutated tumors.”

Dr. Mireille Gillings, CEO and Executive Chair of Huya Bio International, stated: “We are delighted to add a KRAS inhibitor to our oncology portfolio, particularly to explore its potential in combination with our SHP inhibitor for the treatment of various solid tumors. We are pleased to have an outstanding partner like Jeyou Pharma to jointly develop treatment options that will benefit patients worldwide.”